Anti-mesothelin chimeric antigen receptor (CAR) constructs and uses thereof
AssigneeNanjing Legend Biotech Co., Ltd.
InventorsQing Dai, Jian Liu, Shuai Yang, Kun Jiang, Yuanyuan Peng, Chen Hu, Shu Wu
Life of this patent
Estimating the term…
Abstract
Described herein are T cells engineered to express a chimeric antigen receptor (CAR), such as an anti-mesothelin CAR alone or in combination with a follicle-stimulating hormone receptor (FSHR) binding domain and/or a dominant negative transforming growth factor-β receptor II (dnTGFβRII) for the treatment of diseases associated with mesothelin expression. Also described are T cells engineered to express a modified T cell receptor (TCR).
Claims24
An antibody or antigen binding fragment that specifically binds mesothelin, comprising:
- a single domain antibody (sdAb) comprising a complementarity determining region 1 (CDR1), a CDR2 and a CDR3 having the polypeptide sequences of:
- a. SEQ ID NOs:66, 134, and 202, respectively;
- b. SEQ ID NOs:67, 135, and 203, respectively;
- or
- c. SEQ ID NOs:34, 102, and 170, respectively.
A polynucleotide comprising a first nucleotide sequence encoding a chimeric antigen receptor (CAR), wherein the CAR comprises:
- (a) an extracellular domain comprising an antigen binding fragment comprising:
- a single domain antibody (sdAb) comprising a complementarity determining region 1 (CDR1), a CDR2 and a CDR3 having the polypeptide sequences of:
- (i). SEQ ID NOs:
- 66, 134, and 202, respectively;
- (ii). SEQ ID NOs:
- 34, 102, and 170, respectively;
- or
- (iii). SEQ ID NOs:
- 67, 135, and 203, respectively;
- (b) a transmembrane domain;
- and
- (c) an intracellular signaling domain.
A polynucleotide comprising a nucleotide sequence encoding a chimeric antigen receptor (CAR), wherein the CAR comprises:
- (a) an extracellular domain comprising a first polypeptide that binds specifically to a follicle-stimulating hormone receptor (FSHR) and an antigen binding fragment comprising:
- a single domain antibody (sdAb) comprising a complementarity determining region 1 (CDR1), a CDR2 and a CDR3 having the polypeptide sequences of:
- (i). SEQ ID NOs:
- 66, 134, and 202, respectively;
- (ii). SEQ ID NOs:
- 34, 102, and 170, respectively;
- or
- (iii). SEQ ID NOs:
- 67, 135, and 203, respectively;
- (b) a transmembrane domain;
- and
- (c) an intracellular signaling domain.
Dependencies are inferred from the claim text.